CSIMarket Company Name, Ticker, Customers, else..


Heron Therapeutics Inc   (NASDAQ: HRTX)
Other Ticker:  
 

Heron Therapeutics Inc

HRTX's Fundamental analysis



Looking into Heron Therapeutics Inc growth rates, revenue grew by 12.33 % in the first quarter of 2025 from the same quarter a year ago.

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.5 %

Heron Therapeutics Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on HRTX's Growth


Heron Therapeutics Inc
realized a net loss in trailing twelve months.

Heron Therapeutics Inc realized cash reduction of $ -0.01 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


• More on HRTX's Valuation
 
 Total Debt (Millions $) 150
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 450,784
 Net Income/Employee (TTM) $ -23,735
 Receivable Turnover (TTM) 1.98
 Tangible Book Value (Per Share $) -0.14

Heron Therapeutics Inc
realized net loss in trailing twelve months.

Heron Therapeutics Inc realized cash outflow of $ -0.01per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


• More on HRTX's Valuation

•  Market Capitalization (Millions $) 370
•  Shares Outstanding (Millions) 197
•  Employees 328
•  Revenues (TTM) (Millions $) 148
•  Net Income (TTM) (Millions $) -8
•  Cash Flow (TTM) (Millions $) -1
•  Capital Exp. (TTM) (Millions $) -2
•  Total Debt (Millions $) 150
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 450,784
•  Net Income/Employee(TTM) $ -23,735
•  Receivable Turnover Ratio (TTM) 1.98
•  Tangible Book Value (Per Share $) -0.14

•  Market Capitalization (Millions $) 370
•  Shares Outstanding (Millions) 197
•  Employees 328
•  Revenues (TTM) (Millions $) 148
•  Net Income (TTM) (Millions $) -8
•  Cash Flow (TTM) (Millions $) -1
•  Capital Exp. (TTM) (Millions $) -2


    HRTX's Profitability Comparisons
Heron Therapeutics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 8.2 % from 10.04 % in IV. Quarter.

Heron Therapeutics Inc net profit margin of 6.85 % is currently ranking no. 42 in Major Pharmaceutical Preparations industry, ranking no. 104 in Healthcare sector and number 1277 in S&P 500.


Profitability by Segment
Total 6.85 %



  Ratio
•   Capital Ratio (MRQ) 2.4
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.66
•  Inventory Turnover Ratio (TTM) 0.76



Heron Therapeutics Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 8.2 % from 10.04 % in IV. Quarter.

Heron Therapeutics Inc net profit margin of 6.85 % is currently ranking no. 42 in Major Pharmaceutical Preparations industry, ranking no. 104 in Healthcare sector and number 1277 in S&P 500.

• More on HRTX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com